Rhumbline Advisers Raises Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Rhumbline Advisers increased its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 23.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 121,595 shares of the company’s stock after acquiring an additional 23,266 shares during the period. Rhumbline Advisers owned approximately 0.14% of Dyne Therapeutics worth $4,291,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Trexquant Investment LP acquired a new stake in shares of Dyne Therapeutics in the fourth quarter valued at $304,000. Rafferty Asset Management LLC raised its holdings in Dyne Therapeutics by 17.7% in the fourth quarter. Rafferty Asset Management LLC now owns 164,041 shares of the company’s stock valued at $2,182,000 after acquiring an additional 24,632 shares in the last quarter. Commodore Capital LP purchased a new position in Dyne Therapeutics in the fourth quarter worth approximately $11,970,000. Frazier Life Sciences Management L.P. acquired a new position in Dyne Therapeutics during the 4th quarter worth approximately $15,758,000. Finally, Octagon Capital Advisors LP increased its position in shares of Dyne Therapeutics by 14.4% in the 4th quarter. Octagon Capital Advisors LP now owns 792,945 shares of the company’s stock valued at $10,546,000 after purchasing an additional 100,000 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Stock Performance

Shares of NASDAQ DYN opened at $34.40 on Tuesday. The firm has a market cap of $3.01 billion, a P/E ratio of -8.66 and a beta of 1.07. Dyne Therapeutics, Inc. has a 1 year low of $6.40 and a 1 year high of $47.45. The firm’s 50 day moving average price is $41.43 and its 200 day moving average price is $33.43.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.02. As a group, equities analysts predict that Dyne Therapeutics, Inc. will post -2.96 EPS for the current year.

Insider Buying and Selling at Dyne Therapeutics

In related news, COO Susanna Gatti High sold 29,787 shares of the firm’s stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $35.01, for a total value of $1,042,842.87. Following the transaction, the chief operating officer now owns 148,792 shares in the company, valued at $5,209,207.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, CEO John Cox bought 32,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The shares were acquired at an average cost of $33.04 per share, for a total transaction of $1,057,280.00. Following the acquisition, the chief executive officer now owns 8,000 shares in the company, valued at approximately $264,320. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Susanna Gatti High sold 29,787 shares of the stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $35.01, for a total transaction of $1,042,842.87. Following the completion of the sale, the chief operating officer now directly owns 148,792 shares of the company’s stock, valued at approximately $5,209,207.92. The disclosure for this sale can be found here. 20.77% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research firms have recently commented on DYN. Morgan Stanley increased their price objective on Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Jefferies Financial Group boosted their target price on shares of Dyne Therapeutics from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Monday, May 20th. JPMorgan Chase & Co. upped their price target on shares of Dyne Therapeutics from $39.00 to $43.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 9th. Stifel Nicolaus boosted their target price on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Finally, Oppenheimer restated an “outperform” rating and set a $55.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. One equities research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.40.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.